Everything on M&A & Biotech

Merck's $6.7 billion acquisition of Turnstone Pharmaceuticals is reigniting M&A activity in the biotech sector, driven by large pharma's need for pipeline diversification and innovation.

Impact: Provides liquidity and valuation support for mid-cap biotech firms, encouraging strategic partnerships and accelerating deal-making in therapeutic development.

— from AI Pivot, Biotech M&A, and Space Economy Shifts · Alles auf Aktien – Die täglichen Finanzen-News· Mar 26, 2026